Cue Biopharma Cash Flow Conversion Efficiency
Cue Biopharma cash flow conversion efficiency. Based on the latest financial reports, Cue Biopharma (CUE) has a cash flow conversion efficiency ratio of -0.681x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.02 Million) by net assets ($13.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cue Biopharma (2015–2024)
Cash flow conversion efficiency of Cue Biopharma from 2015 to 2024. This chart illustrates how Cue Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cue Biopharma stock price for real-time trading data and today's change.
Cue Biopharma Cash Flow Conversion Ratio Explained
Cue Biopharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cue Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cue Biopharma ranked by their cash flow conversion efficiency. Also see Cue Biopharma market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spackman Equit
V:SQG
|
0.023x |
|
4C Group AB
ST:4C
|
0.019x |
|
Tayih Lun An Co Ltd
TWO:8107
|
0.010x |
|
Wir Asia Tbk PT
JK:WIRG
|
0.022x |
|
5Th Planet Games A/S
OL:5PG
|
0.004x |
|
Keller Group PLC
LSE:KLR
|
0.082x |
|
Birman Wood and Hardware Ltd
TA:BIRM
|
0.326x |
|
Inmobiliaria Park Rose Iberoamericana SOCIMI SA
MC:YPARK
|
0.003x |
Annual Cash Flow Conversion Efficiency for Cue Biopharma (2015–2024)
The table below shows the annual cash flow conversion efficiency of Cue Biopharma from 2015 to 2024. Review how financially flexible is Cue Biopharma to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.50 Million | $-36.33 Million | -2.076x | -92.66% |
| 2023-12-31 | $37.09 Million | $-39.96 Million | -1.078x | -69.30% |
| 2022-12-31 | $65.68 Million | $-41.81 Million | -0.636x | -7.33% |
| 2021-12-31 | $65.49 Million | $-38.84 Million | -0.593x | -44.01% |
| 2020-12-31 | $78.91 Million | $-32.49 Million | -0.412x | +27.02% |
| 2019-12-31 | $54.58 Million | $-30.80 Million | -0.564x | +27.43% |
| 2018-12-31 | $33.97 Million | $-26.41 Million | -0.777x | -292.87% |
| 2017-12-31 | $61.61 Million | $-12.19 Million | -0.198x | +49.69% |
| 2016-12-31 | $15.17 Million | $-5.97 Million | -0.393x | -64.64% |
| 2015-12-31 | $6.94 Million | $-1.66 Million | -0.239x | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more